Oliver's mTOR Atlas Evidence Platform
Reading level
Mode

Satomi Miwa

Mitochondrial biologist who contributed to Newcastle studies on rapamycin in NF-κB-driven ageing mice and on basal mitophagy as a brake on cellular senescence.

Lecturer in Translational Biology of Ageing, Biosciences Institute, Newcastle University · PhD in Biochemistry, University of Cambridge (Martin Brand lab)

Biosciences Institute, Newcastle University (Newcastle upon Tyne, England, United Kingdom) ↗ Lab lineagetrained under Martin D. Brand →

Satomi Miwa Portrait: Alliance for Healthy Aging

Miwa is a co-author on the 2018 study in which rapamycin improved healthspan but not inflammaging or lifespan in nfkb1 knockout mice (COR2018). She is also a co-author on the 2024 paper showing that basal mitophagy falls in senescent and aged human cells and is needed for the anti-senescence effect of rapamycin (KEL2024).

She trained first as a sport scientist, then did a PhD in biochemistry with Martin Brand at Cambridge on mitochondrial reactive oxygen species and ageing. At Newcastle she studies mitochondrial function in ageing and senescent-cell therapies.

Milestones in the Atlas

A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.

YearEvidenceStudy
2018 A Rapamycin improves healthspan but not inflammaging in nfκb1(-/-) mice. COR2018 Co-author: rapamycin improved frailty and memory in nfkb1 mice without reducing inflammaging.
2024 M Suppressed basal mitophagy drives cellular aging phenotypes that can be reversed by a p62-targeting small molecule KEL2024 Co-author: loss of basal mitophagy drives senescence; mitophagy needed for rapamycin's effect.

Co-authors in the Atlas

People with a profile here who share at least one study with Satomi Miwa.

Every researcher with a profile →

← All researchers

Was this page useful?
Spotted something wrong or out of date about Satomi Miwa?